Skip to main content
Equibles

CUVL · Clinuvel Pharmaceuticals Ltd

Track CUVL — free

Use CUVL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CUVL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.13 -0.11 (-2.10%)
Rebalance outlook locked
Market Cap
$264.55M
Shares
50.49M
Volume · Oct 20 2219 Avg daily vol (3M) 13.33K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.24 Open$5.24 Day$5.24–5.40 52W close$5.06–8.75 Avg vol 30d11K Short int12K · 0.0% float · 1.1d Short vol20% DataJan 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
0.7%
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-33.8%
Trailing year
Short interest
0.0%
Latest settlement · 1.1 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −15%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 5%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −10%
trailing
6-month return −21%
trailing
YTD return −38%
this year
Relative strength −28%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.02% of float · ▼ -54.4% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 24
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 50%
annualized · 1-yr
Max drawdown −42%
past year
ATR 4.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
5% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.02% of float · ▼ -54.4% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $5 Now $5 · 5% Range high $9
vs 200-day avg -25% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CUVL
Clinuvel Pharmaceuticals Ltd
this stock
$264.55M -38.2% — — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +10.7% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +669.4% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +1.3% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Falling
Shares short
12.1K
Days to cover
1.1d
Change
-14.4K sh
View
Short Volume
Short vol %
20%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
70
Value
$394
As of
Sep 28, 2026
View
Off-Exchange
Off-exchange %
41.4%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 15, 2026
This year
14

Clinuvel Pharmaceuticals Limited notified the Australian Securities Exchange of the cessation of securities through an Appendix 3H notification.

View

Performance

5D 20D 120D MTD YTD
CUVL -6.2% -9.7% -20.6% -12.1% -38.2%
SPY -1.5% -0.9% +7.7% +0.5% +12.4%
vs SPY -4.7% -8.8% -28.3% -12.6% -50.6%

Capital returns

Latest dividend
$0.036 / share · ex Sep 8, 2026
Raised 5.9%
Paid (TTM)
$0.036 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1290877 CUSIP 188769103 Visit website Investor relations